BPS2024 Full Program & Abstracts

Exhibitor Registration 8:00 am - 5:00 pm, Registration Bridge West Drug Discovery for Ion Channels XXIV Satellite Meeting 8:00 am - 5:15 pm, Room 107AB Sponsored by AXXAM S.p.A.; Cell Microsystems; Metrion Biosciences; Nanion Technologies; SB Drug Discovery; and Sophion Bioscience Ion channels are an important class of therapeutic drug targets, and mutations in ion channel genes are found to be responsible for an increasing number of diseases. While conventional electrophysiologi cal techniques permit the most detailed and direct study of ion channel function, they are limited due to the manual nature of the method and their low throughput. Because of this, ion channels remain an under represented target class for drug discovery. The advent of higher throughput automated electrophysiology systems changed the face of ion channel drug discovery. Since the inaugural “Drug Discovery for Ion Channels” satellite meeting, there have been many advances in ion channel drug discovery including new instru mentation and techniques. For this year, we propose to continue the “Satellite Meeting” tradition at the Biophysical Society Annual Meeting and review the advances ion channel drug discovery. This year’s meeting will highlight presentations from drug discovery companies, companies that provide ion channel services to drug dis covery companies and companies that provide products to ion channel drug discovery companies, as well as other speakers in the field of ion channel drug discovery, including several academic speakers. 8:00 AM REGISTRATION AND COFFEE 8:30 AM WELCOME AND OPENING REMARKS Ali Yehia SESSION I Chair: Neils Fertig 8:45 AM ENDOLYSOSOMAL CATION CHANNELS AS NOVEL DRUG TARGETS. Key note Speaker: Christian Grimm 9:30 AM TRPML1 SMALL MOLECULE AGONISTS FOR THE TREATMENT OF DEGEN ERATIVE DISEASES. Martin B. Gill 10:00 AM DISCOVERY AND CHARACTERIZATION OF THE FIRST PERIPHERALLY RESTRICTED KV7 CHANNEL POTENTIATORS. Michael Poslusney 10:30 AM COFFEE BREAK SESSION II Chair: Jean-Francois Rolland 11:00 AM AUTOMATED PATCH CLAMP RECORDING OF IPSC-DERIVED CARDIO MYOCYTES. Alfred George 11:30 AM STRUCTURAL INSIGHT INTO REGULATION OF KAINATE RECEPTORS. Nami Tajima

12:00 PM PHARMACOLOGIC CHARACTERIZATION OF LTGO-33, A SELECTIVE SMALL MOLECULE INHIBITOR OF THE VOLTAGE-GATED SODIUM CHANNEL WITH A UNIQUE MECHANISM OF ACTION. John Gilchrist 12:30 PM LUNCH (PROVIDED) SESSION III Chair: Steve Jenkinson 1:30 PM RESTORING BALANCE IN ESSENTIAL TREMOR: THE THERAPEUTIC PO TENTIAL OF ULIXACALTAMIDE, A SELECTIVE T-TYPE CALCIUM CHANNEL BLOCKER. Kris Kahlig 2:00 PM PIEZO1 - NEW DEVELOPMENTS AND INNOVATION. David Beech 2:30 PM SAGE-718, A FIRST-IN-CLASS NEUROACTIVE STEROID NMDA RECEPTOR PAM, AS A POTENTIAL THERAPEUTICS FOR COGNITIVE IMPAIRMENT AS SOCIATED WITH NEURODEGENERATIVE DISEASES. Jacob Beckley 3:00 PM COFFEE BREAK SESSION IV Chair: Daniel Sauter 3:30 PM KNOTBODIES - FUSING KNOTTINS INTO ANTIBODY CDR LOOPS TO GEN ERATE POTENT, SELECTIVE AND LONG-ACTING ION CHANNEL MODULA TORS. Edward Humphries 4:00 PM REVERSE USE-DEPENDENCE OF NAV1.8 INHIBITORS. Bruce Palmer Bean 4:30 PM TITLE TO BE ANNOUNCED. Earl Gordon 5:00 PM CLOSING REMARKS Ali Yehia Registration 3:00 pm - 5:00 pm, Registration Bridge West New Council Orientation 3:30 pm - 4:30 pm, Marriott Conference Suite II Joint Council Reception, Dinner, and Meeting 5:00 pm - 9:00 pm, Marriott Independence Ballroom

F R I D A Y

2